Browse By Cell Line Result Page of OvirusTdb
The total number of records retrieved from this search are 18. Click on ID to see further detail.
IDOV_3368 | Virus nameReovirus | Virus strainRecombinant reovirus T1L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationMutant in L1 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration10 pfu | In-vitro result80% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3369 | Virus nameReovirus | Virus strainRecombinant reovirus T1L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationMutant in L1 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration100 pfu | In-vitro result70% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3370 | Virus nameReovirus | Virus strainRecombinant reovirus T1L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationMutant in L1 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration1000 pfu | In-vitro result70% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3371 | Virus nameReovirus | Virus strainRecombinant reovirus T1L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationMutant in L1 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration10 pfu | In-vitro result60% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3372 | Virus nameReovirus | Virus strainRecombinant reovirus T1L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationMutant in L1 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration100 pfu | In-vitro result40% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3373 | Virus nameReovirus | Virus strainRecombinant reovirus T1L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationMutant in L1 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration1000 pfu | In-vitro result20% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3374 | Virus nameReovirus | Virus strainRecombinant reovirus T1L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationMutant in L1 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration10 pfu | In-vitro result65% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3375 | Virus nameReovirus | Virus strainRecombinant reovirus T1L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationMutant in L1 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration100 pfu | In-vitro result20% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3376 | Virus nameReovirus | Virus strainRecombinant reovirus T1L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationMutant in L1 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration1000 pfu | In-vitro result100% cell killing after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3377 | Virus nameReovirus | Virus strainRecombinant reovirus T3L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationSubstitution mutant in T3 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration10 pfu | In-vitro result90% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3378 | Virus nameReovirus | Virus strainRecombinant reovirus T3L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationSubstitution mutant in T3 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration100 pfu | In-vitro result80% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3379 | Virus nameReovirus | Virus strainRecombinant reovirus T3L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationSubstitution mutant in T3 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration1000 pfu | In-vitro result70% cell viability after 24 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3380 | Virus nameReovirus | Virus strainRecombinant reovirus T3L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationSubstitution mutant in T3 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration10 pfu | In-vitro result80% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3381 | Virus nameReovirus | Virus strainRecombinant reovirus T3L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationSubstitution mutant in T3 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration100 pfu | In-vitro result50% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3382 | Virus nameReovirus | Virus strainRecombinant reovirus T3L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationSubstitution mutant in T3 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration1000 pfu | In-vitro result30% cell viability after 48 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3383 | Virus nameReovirus | Virus strainRecombinant reovirus T3L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationSubstitution mutant in T3 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration10 pfu | In-vitro result80% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3384 | Virus nameReovirus | Virus strainRecombinant reovirus T3L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationSubstitution mutant in T3 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration100 pfu | In-vitro result50% cell viability after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |
IDOV_3385 | Virus nameReovirus | Virus strainRecombinant reovirus T3L | Virus genome typeRNA | Virus familyReoviridae | Virus genome modificationSubstitution mutant in T3 gene | Virus aloneYes | Virus in combination with drug/radiationNo | Immune gene insertion in viral genomeNo | Source of cell lineATCC | Origin of cell lineHuman lung cancer cell line | Cell lineH1563 | Concentration of cell line1.0E+4 cells per well | In-vitro toxicityNA | AssayCell-titer-glo assay | In-vitro virus concentration1000 pfu | In-vitro result100% cell killing after 72 hours | Model organismNo | In-vivo virus concentrationNo | In-vivo toxicityNA | In-vivo resultNo response | Mode of deliveryNA | Pathway inducedInduction of apoptosis | Immunogenic effectNA | Clinical trialNA | PMID28587298 |